Range of suitable patients: CDEC discussed the uncertainty in the number of patients with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some people who will be labeled as obtaining gentle or moderate disease may have a severe bleeding phenotype, which… Read More